4SC Receives Milestone Payment from Research Collaboration with SKK
News Oct 15, 2012
4SC AG has announced that it has received a milestone payment from the Japanese pharmaceutical company Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya (SKK) under a previously-concluded research collaboration.
The milestone payment will go to 4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG specializing in the early-stage biopharmaceutical research and discovery of new drug substances.
Under the research collaboration, 4SC had contributed its know-how in the field of medicinal chemistry together with its expertise in computerized (in silico) screening and modelling for the rapid discovery, selection and optimization of new drug substances (hits and leads) to investigate new classes of substances for the potential therapy of metabolic diseases.
In its pharmaceutical research and development work, SKK has now achieved decisive progress with an optimized chemical compound resulting from this collaboration, which triggered the contractually-agreed milestone payment.
Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director of 4SC Discovery GmbH commented: 'We are very pleased to have received this milestone payment. This success further stresses our long-standing research expertise and the capabilities of our core technology for the discovery and optimization of new pharmaceutical compounds, a technology that we have been marketing more actively since early 2012 with the newly-launched 4SC Discovery. Our special thanks are due to our partner SKK for the fruitful and pleasant collaboration. We intend to use this and, in the future, similar ventures to further strengthen the business of both 4SC Discovery and the entire 4SC Group.'
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE